Patent ID: 7528111

Claim:
A method of vaccinating a subject being treated with soluble CTLA4 molecule comprising administering a vaccine 14±3 days prior to the administration of the soluble CTLA4 molecule dose, wherein the vaccine is selected from the group consisting of influenza vaccine, pneumococcal vaccine and tetanus toxoid vaccine, wherein the soluble CTLA4 molecule is CTLA4lg as shown in FIG. 6 beginning with methionine at position +1 or with alanine at position −1 and ending with lysine at position +357 or glycine at position +356 or L104EA29Ylg as shown in FIG. 8 beginning with methionine at position +1 or with alanine at position −1 and ending with lysine at position +357 or glycine at position +356.